Dapagliflozin alleviates mitochondrial damage in the myocardium under diabetic conditions by targeting sortilin
Our findings uncover a novel molecular mechanism through which dapagliflozin improves myocardial mitochondrial injury under diabetic conditions, suggesting SORT1 as a potential therapeutic target for treating myocardial injury in diabetes.
Authors
- Qi Shu (ORCID: https://orcid.org/0000-0002-9196-1776)
- Lijuan Kong (ORCID: https://orcid.org/0009-0005-7194-1443)
- Fang Li (ORCID: https://orcid.org/0000-0002-7617-6534)
- Xiaoyu Yang (ORCID: https://orcid.org/0000-0001-8858-8619)
- Yan Zhang (ORCID: https://orcid.org/0000-0003-3367-5832)
- Ying Cui (ORCID: https://orcid.org/0000-0002-7072-689X)
- En Li (ORCID: https://orcid.org/0000-0002-7144-961X)
- Han Li (ORCID: https://orcid.org/0000-0002-7163-1358)
- Yifeng Gao (ORCID: https://orcid.org/0009-0005-0103-3837)
Institutions
- Zhengzhou University (CN)
- Zhengzhou University of Science and Technology (CN)
- Second Affiliated Hospital of Zhengzhou University (CN)
- First Affiliated Hospital of Xi'an Jiaotong University (CN)
Publication Details
- Journal
- Cellular and Molecular Life Sciences
- Published
- 2025-06-25
- DOI
- https://doi.org/10.1007/s00018-025-05793-8
- Citations
- 2
- Primary Topic
- Pancreatic function and diabetes
- Type
- article
- Field-Weighted Citation Impact
- 4.01
Funders
- Zhengzhou University